TCM
RMD icon

Triumph Capital Management’s ResMed RMD Stock Holding History

Triumph Capital Management’s Portfolio RMD Stock Details RMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$974 Sell
5
-7
-58% -$1.45K ﹤0.01% 1668
2026
Q1 		$2.69K Buy
12
+8
+200% +$1.99K ﹤0.01% 1488
2025
Q4 		$963 Buy
+4
New +$1.02K ﹤0.01% 1580

Other funds holding RMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Triumph Capital Management's RMD Position: Q2 2026 in Review

Triumph Capital Management reduced its ResMed (RMD) stake by 58% in Q2 2026, selling an estimated $1.45K and leaving 5 shares worth $974. The position accounts for ﹤0.01% of the portfolio, ranked #1668.

Triumph Capital Management first reported a position in RMD in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.69K in Q1 2026. 880 funds tracked by Wall St. Rank hold RMD as of Q2 2026.

  • Triumph Capital Management held 5 shares of ResMed worth $974 as of Q2 2026.
  • Triumph Capital Management sold 7 ResMed shares in Q2 2026, an estimated $1.45K.
  • ResMed made up ﹤0.01% of Triumph Capital Management's portfolio in Q2 2026, its #1668 holding.
  • Triumph Capital Management first reported a position in ResMed in Q4 2025 and has held it in 3 quarters since.
  • Triumph Capital Management's ResMed position peaked at $2.69K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held ResMed as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.